A Pivotal study of paxalisib in patients with brain metastases
Latest Information Update: 09 Oct 2024
At a glance
- Drugs Paxalisib (Primary)
- Indications Brain metastases
- Focus Registrational; Therapeutic Use
Most Recent Events
- 02 Oct 2024 discussions for a potential According to a Kazia Therapeutics media release, pivotal registration study to evaluate this unique combination therapy for patients with PI3K mutant brain metastases are ongoing
- 28 Feb 2024 New trial record
- 21 Feb 2024 According to a Kazia Therapeutics media release, the company is preparing to engage with the Food and Drug Administration to discuss the data of the phase 1 study, and seek guidance on the conduct of this pivotal registration study.